BREAST CANCER

The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.

Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.

In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.

Phase 3 trial shows trastuzumab botidotin boosts PFS and response rates vs T-DM1 in pretreated HER2-positive metastatic breast cancer, with manageable ocular toxicity.

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

SERENA-4 missed its PFS end point for camizestrant plus palbociclib vs anastrozole plus palbociclib in untreated advanced breast cancer.

NHIS analysis reveals major screening gaps for disabled adults—especially self-care limits—while at-home stool tests boost colorectal screening access.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify eligible patients for the camizestrant regimen.

Phase 3 Neo-Healer shows anbenitamab plus HB1801 boosts complete response rates in ERBB2-positive breast cancer, with manageable safety.

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography rather than one-size-fits-all follow-up.

Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2– metastatic breast cancer, after VIKTORIA-1 shows longer PFS than alpelisib.

Two peer-reviewed publications cite ProSense cryoablation FDA authorization and ASBrS guidelines, and extend its use to axillary lymph node disease.

The FDA has granted fast track designation to ETX-19477, an oral PARG inhibitor, for BRCA-mutated, HR+/HER2– unresectable or metastatic breast cancer.

A guide to breast cancer biomarker testing, from ER/PR and HER2-low status to PIK3CA, AKT1, and ESR1 mutations across diagnosis and disease progression.

The multicenter PRO B trial found that weekly ePRO monitoring with alert-based nurse contact reduced fatigue vs usual care in metastatic breast cancer.

A secondary analysis of the phase 3 RxPONDER trial found that premenopausal women with low baseline AMH did not benefit from added chemotherapy vs endocrine therapy alone.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.

Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.